"Designing Growth Strategies is in our DNA"

Middle East & Africa Human Insulin Market Size, Share & COVID-19 Impact Analysis, By Type (Analog Insulin, and Traditional Insulin), By Diabetes Type (Diabetes 1, and Diabetes 2), By Distribution Channel (Hospital Pharmacy, and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI107470

 


To get information on various segments, share your queries with us

 

  ATTRIBUTE

  DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year

2022

Forecast Period

2023-2030

Historical Period

2018-2020

Unit

Value (USD Billion)

Growth Rate

CAGR of 0.8% from 2023-2030

Segmentation

Type; Diabetes Type; Distribution Channel; and Country/Sub-Region

By Type

  • Analogue Insulin
    • Long-acting
    • Fast-acting
    • Premix
  • Traditional Human Insulin
    • Long-acting + Intermediate
    • Short-acting
    • Fast-acting
    • Premix

By Diabetes Type

  • Diabetes 1
  • Diabetes 2

By  Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By  Country/ Sub-Region

  • GCC (By Diabetes Type)
  • South Africa (By Diabetes Type)
  • Rest of Middle East & Africa (By Diabetes Type)
  • 2019-2030
  • 2022
  • 2019-2021
  • 109
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann